Journal
INTERNAL MEDICINE
Volume 59, Issue 18, Pages 2245-2248Publisher
JAPAN SOC INTERNAL MEDICINE
DOI: 10.2169/internalmedicine.3726-19
Keywords
iCIs; nivolumab; PD-1; CTLs
Categories
Funding
- Ministry of Education, Culture, Sport, Science and Technology of Japan [16K09335, 19K08374]
- Ministry of Health, Labour and Welfare
- Grants-in-Aid for Scientific Research [16K09335, 19K08374] Funding Source: KAKEN
Ask authors/readers for more resources
Recently, immune checkpoint inhibitors (iCIs) have been used to treat cancers. Once some of the iCIs for the treatment of hepatocellular carcinoma (HCC) are certified in clinical trials, they are likely be administered to HCC patients with hepatitis C virus (HCV). However, the immunopathogenesis of HCV after the administration of iCIs has not been clarified. We experienced a lung cancer patient with HCV infection treated by nivolumab, programmed cell death 1 (PD-1) antibody. HCV-RNA gradually decreased after the start of nivolumab treatment. However, no increase in transaminase was observed during the decline of HCV-RNA. It was thought that HCV-specific cytotoxic T lymphocytes (CTLs) were activated by iCIs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available